AGN Allergan plc

By Micah Maidenberg

Allergan PLC (AGN) reported stronger-than-expected revenue and a smaller loss for the fourth quarter.

The maker of Botox and other drugs on Monday reported $4.35 billion in revenue for the quarter, up about 7% from the year earlier and more than the $4.09 billion analysts polled by FactSet predicted.

Allergan said its loss attributable to shareholders narrowed to $317.2 million, or 97 cents a share, from $4.29 billion, or $12.83 a share, in the fourth quarter of 2018, when the company recorded impairments, affecting results.

Allergan's adjusted earnings for the latest period of $5.22 a share beat forecasts from analysts, who expected $4.57 a share on that metric.

AbbVie Inc. (ABBV) plans on combining with Allergan in a deal the companies believe will be completed in the first quarter.

Write to Micah Maidenberg at micah.maidenberg@wsj.com

(END) Dow Jones Newswires

February 10, 2020 07:31 ET (12:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.